In our lab, we focus on the metabolic interactions that dictate the changes or resilience of the microbiota. Insight into such interactions would enable precise manipulation of gut microbiota composition, thus restoring a balanced community in situ and improving host health. To precisely manipulate the microbiota, we use a multidisciplinary discovery pipeline that consists of next-generation sequencing, bacterial genetics and a mechanistic understanding of bacterial physiology in vivo. This pipeline allows us to discover druggable targets of the microbiota and translate our findings using high-throughput screening.